跳至主要内容
临床试验/NCT01211028
NCT01211028已完成1 期

Safety of Autologous Adipose Derived Stroma/Stem Cells to Treat Critical Leg Ischemia.

University Hospital, Toulouse2 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2009年1月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
13
试验地点
2
主要终点
Number and Nature of Adverse Events : safety and tolerability

研究概览

简要总结

The main purpose of this study is to evaluate the safety and feasibility of regenerative therapy with expanded adipose derived stroma/stem cells sue, administered intramuscularly in patients with critical leg ischemia.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Severe peripheral vascular disease not amenable to bypass or angioplasty
  • Age >40 years old
  • Normal renal function (creatinine < 1.6)
  • Non pregnant female
  • Lifespan > 6 months

排除标准

  • Age <40 years old
  • Refusal to give informed consent and/orCognitively disabled
  • Congestive heart failure or stroke in the last 3 months
  • History of cancer or myeloproliferative disorders
  • Proliferative retinopathy
  • Pregnancy
  • Positive screening test for HIV, Hepatitis B or Hepatitis C
  • Buerger patient
  • Cachexia or predicted impossibility for a biopsy of at least 30 grams of fat tissue
  • Pregnancy or lactation
  • Having been non controlled severe pathology

结局指标

主要结局

Number and Nature of Adverse Events : safety and tolerability

时间窗: 15 days, 1, 2, 3, 4,5, 6 months for adverse events record

To evaluate safety and tolerability related to the intramuscular injection of autologous adipose derived stroma/ stem cells. \[ Designated as safety issue: Yes \]

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验